

Special Issue

Personalized Medicine in Bronchial Asthma

Message from the Guest Editor

Asthma is a heterogeneous disease comprising several phenotypes or endotypes driven by different pathways. The aim is to highlight phenotypes, endotypes, and personal traits that could lead to increased susceptibility to the disease or heightened incidences, and to then use this information as a basis for which tailor-made prevention and treatment strategies can be devised for individuals or groups of patients such that they can receive specific therapies, i.e., the optimal medications that work best for them at the right time without wasting resources on trial and error treatments. Another aim is to address additional factors such as environmental, occupational, psychological, and personality factors which are capable of affecting asthma management but are often ignored. For this Special Issue, we welcome research papers, clinical trials, and reviews addressing factors that could contribute to the use of personalized approaches in addressing asthma.

Guest Editor

Dr. Paraskevi Katsaounou

1. Pulmonary Dept of First ICU Clinic, Evangelismos Hospital, 10676 Athens, Greece
2. School of Medicine, National and Kapodistrian University of Athens, 10561 Athens, Greece

Deadline for manuscript submissions

closed (10 July 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/82869

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).